Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during Long-Term Treatment of Chronic Hepatitis B: A Cross-Sectional Study

Table 3

Blood and urine chemistries at baseline and 3 months after discontinuation of nucleotide analogues in 17 patients with proximal renal tubular dysfunction (RTD).

	At baseline	Three months after drug discontinuation
Creatinine (mg/dL)	1.04 ± 0.2	0.96 ± 0.2	0.005
GFR by CKD-EPI (mL/min)	67.8 ± 17.0	74.6 ± 16.3	0.005
Serum phosphate (mg/dL)	2.5 ± 0.6	3.1 ± 0.6	0.002
Serum uric acid (mg/dL)	3.4 ± 1.1	3.9 ± 1.0	<0.001
Serum potassium (mEq/L)	4.0 ± 0.3	4.0 ± 0.3	0.53
FEPO4 (%)	25.5 ± 9.0	22.5 ± 12.1	0.13
FEUA (%)	22.9 ± 9.2	18.1 ± 8.3	0.003
FEK (%)	9.8 ± 4.7	13.7 ± 14.7	0.40
Median 24-hour urine protein (mg)	252 (55–939)	88.5 (0–355)	0.003

GFR, glomerular filtration rate; FEPO₄, fractional excretion of phosphate; FEUA, fractional excretion of uric acid; FEK, fractional excretion of potassium.
Data are expressed as mean SD unless otherwise indicated.